key: cord-0859265-ilun5apv
authors: Devresse, Arnaud; De Greef, Julien; Yombi, Jean Cyr; Belkhir, Leila; Goffin, Eric; Kanaan, Nada
title: Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients
date: 2022-02-10
journal: Transplant Direct
DOI: 10.1097/txd.0000000000001292
sha: ddd090c594370104dc009ea62cfd68fc976a01e4
doc_id: 859265
cord_uid: ilun5apv

Kidney transplant recipients (KTRs) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have an increased risk of mortality compared with the general population and hemodialysis patients. As these patients are immunosuppressed, it might seem obvious to attribute this excess mortality to the impaired immunity induced by immunosuppression. In line with this reasoning is the low immune response, both cellular and humoral, that KTRs mount in response to the anti–SARS-CoV-2 vaccine; however, acute respiratory distress syndrome associated with coronavirus disease 2019 is triggered by a state of inflammation and cytokine release syndrome that lead to pulmonary damage and increased mortality. In that context, immunosuppressive treatment dampening the immune response could, in theory, be potentially beneficial. This review aims at analyzing the current knowledge on the impact of immunosuppressive treatment on mortality in SARS-CoV-2–infected KTRs, the optimal management of immunosuppression in the coronavirus disease 2019 era, and the vaccine response and management in immunosuppressed KTRs.

T he severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has shaken the world since its initial outbreak in December 2019. As of November 2021, >261 000 000 cases and 5 200 000 deaths have been reported by the World Health Organization, and the numbers continue to rise. 1 Mortality rates by country-provided by the Johns Hopkins University-range from 0.1% to 9.2% with important geographic variations. 2 Kidney transplant recipients (KTRs) infected with SARS-CoV-2 have shown increased death rates. Indeed, data derived from 3 meta-analyses demonstrated mortality rates ranging from 18.6% to 23%, respectively. [3] [4] [5] Moreover, in a multivariate analysis for predictors of mortality in 10 926 coronavirus disease 2019 (COVID-19)-related deaths in England, solid organ transplant (SOT) recipients had the highest hazard ratio of 3.53 (95% confidence interval, 2.77-4.49) compared with hazard ratio of other infected patients including those with comorbidities such as cancer, hematological malignancy, chronic respiratory disease, rheumatoid diseases, and so on. 6 A nationwide cohort in Denmark showed similar results 7 ; however, these studies do not allow us to accurately define the increased mortality rate in KTRs, as SOT recipient groups were heterogeneous and the exact number of KTRs included was not reported. As patients undergoing transplantation receive immunosuppressive treatment to prevent rejection, it might seem obvious to attribute the excess mortality encountered by KTRs infected with SARS-CoV-2 to the impaired immunity secondary to immunosuppression. In line with this reasoning is the lower immune response, both cellular and humoral, that KTRs mount in response to the anti-SARS-CoV-2 vaccine [8] [9] [10] ; however, complications associated with SARS-CoV-2 infection-mainly acute respiratory distress syndrome (ARDS)-are triggered by a state of dysregulated inflammation and cytokine release syndrome that lead to pulmonary damage and increased mortality. [11] [12] [13] In that context, immunosuppressive treatment dampening the immune response could be potentially beneficial.

This review aims at analyzing the current knowledge on (1) the impact of immunosuppressive treatment on mortality, (2) the optimal management of immunosuppression in the COVID-19 era, and (3) the vaccine response and management in immunosuppressed KTRs. from 20% to 32% in KTRs compared with 1% to 14% in the general population, after adjustment for age and comorbidities. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] When compared with hemodialysis patients, the mortality of KTRs also seems higher. 15, 17 Increased mortality in KTRs may indirectly suggest a negative impact of immunosuppression. Indeed, both innate and adaptive immunity are activated following SARS-CoV-2 infection and are necessary to clear the virus. 24, 25 Immunosuppressive agents given after KT affect both innate and adaptive immunity and might impair the immune control of the viral replication. 26 In favor with this assumption, a Spanish national study 27 reported that a SARS-CoV-2 infection occurring in the first 60 d after KT-when the immunosuppressive burden is the most intense-was associated with a significantly increased mortality rate of 45.8%. In agreement with this finding, a report from the European Renal Association COVID-19 Database comparing mortality in KTRs and hemodialysis patients showed that, in a fully adjusted model for age, sex, frailty, and comorbidities, the risk of mortality was higher in KTRs and increased during the first posttransplant year, without, however, association between immunosuppressive treatments and mortality. 17 A large Brazilian multicenter cohort study including 1680 SARS-CoV-2-infected KTRs (65.1% requiring hospitalization) reported a 90-d death rate of 21%. 28 In the multivariate analysis, the use of tacrolimus (Tac) and mycophenolic acid (MPA)-the most commonly used immunosuppressive combination 29 -was independently associated with the risk of death. Although these studies indirectly suggest an impact of immunosuppression, others have failed to demonstrate differences in the outcome between patients transplanted <1 y ago and those transplanted for a longer time, 16 as well as patients receiving induction therapy with lymphocyte depleting agents versus nondepleting agents, 16 suggesting that the degree of immunosuppression does not have a major impact on disease severity and outcome. 30 Moreover, a cytokine release syndrome-arising from an inadequate immune response implicating interleukins, the complement, and intense antibody response to the virushas been identified as responsible for negative outcomes of pneumonia, in which case immunosuppressive agents, including calcineurin inhibitors (CNIs), MPA, and glucocorticoids, could also theoretically be beneficial. 31 In fact, glucocorticoids are currently one of the treatments to have proven efficacy in patients admitted for severe COVID-19 pneumonia. 32 To delineate the role of comorbidities versus immunosuppression on mortality rates, recent studies have compared KTRs infected with COVID-19 to nontransplanted patients with similar comorbidities. Chaudhry et al 33 first showed a similar rate of mortality, need of intensive care unit, and mechanical ventilation support in COVID-19 hospitalized SOT recipients compared with nontransplant controls, suggesting that the transplant status by itself does not confer an increased predictive risk of mortality or severe disease. More recently, studies comparing the clinical outcomes of COVID-19 in patients with SOT to a propensity-matched cohort of nontransplanted patients with similar comorbidities showed similar severity of infection and mortality. [18] [19] [20] 34 These studies conclude that long-term immunosuppression does not seem to increase the risk of developing severe forms of COVID-19; however, it must be underlined that in almost all studies, immunosuppression was decreased when KTRs were hospitalized, although in a nonhomogeneous way. Tables 1 and 2 summarize the main studies-including at least 100 KTRs-that have compared the outcomes of COVID-19 in KTRs versus matched control groups. It is worth noting that the high heterogeneity of these studies in terms of patients included (SOT recipients versus KTRs alone), study design, type, and selection of the control group, and periods of inclusions is most likely one of the main explanations for the contrasting conclusions. Thus, at the current moment, although immunosuppression is a heavy contributor to the comorbidities affecting KTRs that make them at risk of complications and fatal outcome, it is still unclear whether immunosuppression by itself leads to an increased mortality in KTRs.

Lowering immunosuppression-especially antimetabolite drugs-in case of symptomatic SARS-CoV-2 infection has been applied by most KT centers. 35 Table 3 summarizes the main guidelines available regarding the management of immunosuppression in SARS-CoV-2-infected KTRs. [36] [37] [38] [39] [40] [41] However, because randomized data are lacking, the optimal strategy of immunosuppression reduction, as well as its safety and efficacy, is not well defined. Immunosuppression minimization seems logical to unleash the antiviral T-cell response to control the infection. 25 In contrast, maintaining baseline immunosuppression is also a reasonable approach to mitigate the development of an uncontrolled overactivation of the immune response that is associated with the development of ARDS. [11] [12] [13] A randomized controlled trial comparing maintenance versus reduction of immunosuppression (NCT04420364) has been set up, but inclusions were terminated early because of lack of recruitment.

Safety concerns also exist on the middle-and long-term immunological consequences of immunosuppression minimization. Indeed, in other settings, as in BK virus infection, 42 a prolonged and intense minimization has been associated with an increased risk of developing de novo donor-specific antibodies (DSAs). Little is known about the potential risk of DSA development after COVID-19. A recently published case series from 2 KT centers in Spain reported the clinical follow-up of 47 hospitalized KTRs who survived COVID-19. Eighty-three percent had at least 1 immunosuppressive drug withdrawn-mostly the antimetabolite-for a median time 

Guidelines Key recommendations TTS 40 -No strong recommendation -Calibration of dose reduction has to be balanced with the risk of acute rejection ERA 37 -Maintain IS treatments unchanged in KTRs <60 y without pulmonary infiltrates.

-In all other cases, MPA should be stopped, as well as CNI and mTORi if concomitant fever or hypoxia AST 36 -Consider immunosuppression reduction BTS 38 -Stop antiproliferative agents, and consider CNI reduction of 17 d. Up to 3 mo after discharge, no rejection episode or emergence of de novo DSAs were observed, and no significant changes occurred in the calculated panel reactive antibodies. 43 Nevertheless, longer follow-up studies with larger cohorts are necessary to assess the safety of minimization strategies.

Immunosuppressive Drugs and COVID-19: Harmful or Potential Adjuvant Therapy?

A triphasic course in COVID-19 disease has been described. 24 In the first phase, patients have mild symptoms, such as dry cough, malaise, and fever. An adequate response of the innate and adaptive immune systems can eliminate the virus and preclude disease progression to the next stages. 25 In the second phase, viral multiplication and localized inflammation of the lung tissue occur, causing viral pneumonia. A minority of patients with COVID-19 will undergo a transition to the third and most severe phase of illness: a syndrome of systemic hyperinflammation, also referred to as the cytokine storm syndrome, associated with high levels of proinflammatory cytokines release, such as interleukin (IL)-2, IL-6, IL-7, and tumor necrosis factor-alpha. In this phase, patients can develop ARDS and multiorgan failure, which are the main causes of death. [11] [12] [13] In vitro investigations show that some immunosuppressive drugs have antiviral effects against coronaviruses. How immunosuppressive drugs commonly used after KT can potentially affect COVID-19 is discussed below.

Corticosteroids are widely used after KT. They have a wide range of anti-inflammatory and immunomodulatory effects, including inhibition of the synthesis of proinflammatory cytokines, reduction of leukocyte trafficking, and induction of T-lymphocytes apoptosis. 44 They impair innate, T-cell, and humoral immunity. 26 Corticosteroids have been tested in immunocompetent patients infected by SARS-CoV-2 in at least 8 cohort studies and 1 open-label randomized trial. Six cohort studies showed that steroid use was associated with a better clinical outcome in patients with COVID-19 13,45-49 ; however, 2 cohort studies reported opposite results. 50, 51 They found that steroid use was associated with a higher risk of blood stream infections 50 and a lower remission rate. 51 These conflicting results may have resulted from selection bias because of nonrandomization. The RECOVERY trial was an open-label controlled study comparing dexamethasone versus standard of care in hospitalized COVID-19 patients. It showed that dexamethasone was associated with reduced 28-d mortality in patients requiring oxygen supplementation. 32 Effectiveness of steroids in severe COVID-19 was also demonstrated in a meta-analysis. 52 Since then, dexamethasone has been the standard of care in patients with COVID-19 requiring supplemental oxygen; however, as KTRs were excluded from most studies-including RECOVERY-the benefit of increasing steroids in KTRs with symptomatic COVID-19 is still to be proven.

CNIs-Tac and cyclosporine A-are the cornerstone of most immunosuppressive regimens used after KT. They impact innate, cell-mediated, and humoral immunity. 26 In vitro studies suggest that CNIs have antiviral effects on coronaviruses. Cyclosporine A has been shown to inhibit the replication of several coronaviruses in vitro at noncytotoxic concentrations and independently of its immunosuppressive effect. 53, 54 A genome-wide analysis of protein-protein interactions between SARS-CoV (SARS-CoV-1) and human host proteins identified FK506 (Tac)-binding proteins as one of the interaction partners for SARS-CoV proteins. 55 In addition, both FK506 treatment and knock down of FK506-binding proteins 1A and 1B inhibited SARS-CoV replication in vitro. 56 Finally, cyclophilins, the binding proteins of cyclosporine A, catalyze the cis/trans isomerization of propyl peptide bonds. This is an essential step in the correct folding of proteins, such as cellular and viral proteins. 57 This function of cyclophilin is found to be important for the replication of SARS-CoV-2. 31 However, there is no clinical evidence supporting that CNIs may improve the clinical outcomes of COVID-19 in KTRs or in the general population. There is also no evidence that reducing or interrupting CNIs improve the clinical outcome of SARS-CoV-2-infected KTRs. A phase 2 clinical trial is ongoing to test the efficacy of conversion from Tac to voclosporin-a third-generation CNI-to reduce the time of viral clearance in SARS-CoV-2-infected KTRs with mild to moderate symptoms on dual immunosuppressive treatment of steroids and Tac (NCT04701528). Current recommendations regarding management of CNI consider reducing doses or drug cessation depending on the severity of the infection (Table 3) .

MPA and azathioprine are the most commonly used antimetabolites after KT. Both drugs inhibit purine synthesis, affecting T-and B-cell proliferation. 26 MPA was shown to inhibit viral replication of 4 different coronaviruses (but not SARS-CoV-2) in cell culture. 58 One in vitro study found that MPA inhibits SARS-CoV-2 replication in VeroE6/TMPRSS2 cells. 59 In another study, 60 human pluripotent stem cells were differentiated into lung organoids and then infected with SARS-CoV-2. In these lung organoids, MPA inhibited viral replication of SARS-CoV-2. To the best of our knowledge, there are no data about azathioprine.

Most guidelines recommend considering MPA cessation in KTRs presenting symptomatic COVID-19. In a large multicenter cohort study of SARS-CoV-2-infected KTRs in Brazil, MPA, when associated with Tac, was an independent risk factor of mortality 28 ; however, there is currently no strong clinical evidence showing that MPA interruption modifies the outcome of patients.

Sirolimus and everolimus are inhibitors of the mechanistic target of rapamycin (mTORi). They inhibit protein synthesis, cell cycle progression, and cell growth, 61 impacting mostly innate and cell-mediated immunity. 26 The use of mTORi after KT is associated with a reduced incidence of several viral infections, such as cytomegalovirus and BK virus. 62, 63 mTORi's were shown to inhibit MERS-CoV replication in vitro. 64 A work based on network drug repurposing suggested sirolimus as a potential treatment for COVID-19. 65 At least 3 clinical trials are ongoing (NCT04341675, NCT04461340, and NCT04948203) to evaluate the effectiveness of mTORi initiation in the general population hospitalized for COVID-19. In KTRs, mTORi did not emerge as protective against the development of severe COVID-19 outcomes; however, it is important to keep in mind that these drugs were interrupted most of the time in hospitalized KTRs with severe diseases by fear of their potential negative impact on the pulmonary involvement associated with COVID-19.

Tocilizumab, an anti-IL-6 receptor, has shown promising results in the treatment of active and chronic antibody-mediated rejection in KTRs. 66 ,67 IL-6 is an important proinflammatory cytokine involved in the acute phase response and differentiation and function of B and T cells. 68 IL-6 is also an important actor in the cytokine storm associated with severe forms of COVID-19. [11] [12] [13] Consequently, tocilizumab has been investigated in COVID-19 patients in several cohort studies and a phase 3 placebo-controlled trial. In 3 cohort studies, tocilizumab use was associated with lower mortality and intensive care unit admission rates 69, 70 ; however, other cohort studies reported contradictory results. 50,71-75 A phase 3 placebo-controlled trial showed that tocilizumab treatment in patients hospitalized with COVID-19 pneumonia was effective to improve a composite end point including mechanical ventilation initiation or death by day 28 76 ; however, in another phase 3 placebo-controlled trial, tocilizumab was not superior to the placebo to improve clinical status in patients hospitalized for severe COVID-19. 77 Finally, a meta-analysis showed that tocilizumab was superior to usual care or the placebo to improve a composite end point of progression to mechanical ventilation, extracorporeal membrane oxygenation, or death. 78 Nevertheless, the effectiveness of tocilizumab to improve mortality alone has still to be demonstrated. Small case series suggest that tocilizumab might be used safely with moderate efficacy in COVID-19 KTRs. Pereira et al 79 showed in a case series of 29 hospitalized SOT recipients with severe COVID-19 that tocilizumab could be used safely but was not associated with decreased incidence of 90-d mortality compared with a matched cohort of SOT recipients who did not receive the drug.

Induction immunosuppression at KT typically consists of basiliximab or thymoglobulin. 80 Thymoglobulin is a T cell-depleting agent, especially used in sensitized recipients. Basiliximab is a CD25 receptor antagonist. Thymoglobulin has been associated with an increased risk of viral infection-cytomegalovirus and BK virus-compared with basiliximab. 81 There are currently no published data about the impact of induction therapy on COVID-19. The TANGO trial 16 reported the outcomes of 144 KTRs hospitalized for COVID-19 and did not find a significant difference between KTRs who received induction therapy with lymphocyte depleting agents versus those who did not.

Rituximab, a monoclonal anti-CD20 antibody, is commonly used in HLA-or ABO-incompatible KTs or as treatment of antibody-mediated rejection. A French multicenter cohort study recently showed that treatment with rituximab in patients with inflammatory rheumatic and musculoskeletal diseases was associated with more severe COVID-19 82 ; however, published data on KTRs treated with rituximab are lacking.

Belatacept inhibits T-cell activation through costimulation blockade, allowing a CNI-free regimen. Its impact on the risk of developing severe COVID-19 infection has not been well evaluated so far. Although some authors have suggested that belatacept might mitigate the cytokine storm, resulting in a mild form of COVID-19 in KTRs, evidence is very weak and not currently tested in clinical trials. 83 The French Society of Transplantation recommends belatacept cessation in KTRs infected with SARS-CoV-2 41 (Table 3) .

Great hopes were placed in the early vaccination of all immunocompromised patients to reduce the rate of severe forms of COVID-19; however, disappointing results emerged from KTR cohort studies regarding the humoral response rates after 2 doses of mRNA vaccines that ranged from 29.9% to 54% (Table 4) . 9, 85, 87, 89, 90 These results contrast with the robust humoral response rates observed in the general population 91 and also in chronic dialysis populations. [92] [93] [94] Cellular response rates were also low. Bertrand et al 8 showed a 57.8% T-cell response rate in 26 KTRs after 2 doses of the BNT162b2 vaccine, using an ELISpot immunoassay. Cucchiari et al 9 demonstrated a 54.7% T-cell response rate after the second dose of the mRNA-1273 vaccine in 117 SARS-CoV-2-naive transplant patients, also using an ELISpot immunoassay. We recently reported a cellular response rate of 32.2% (Interferon-Gamma-Release-Assay test) in a cohort of 90 SARS-CoV-2-naive KTRs 1 mo after the second dose of the mRNA BNT162b2 vaccine. 10 Case series of severe SARS-CoV-2 infections in fully vaccinated KTRs have been reported. 95, 96 A recent large multicenter study showed that compared with 101 million fully vaccinated adults in the United States, fully vaccinated SOT recipients (n = 18.215) had an 82-fold higher risk of breakthrough infection and 485-fold higher risk of breakthrough infection with associated hospitalization and death. 97 These data emphasize the importance of the adaptative immune response in the defense against the virus. Regarding such poor results, a third dose of mRNA vaccine was tested in a case series and 1 randomized trial and resulted in a substantial increase of humoral response rates at around 70% 84, [86] [87] [88] (Table 4 ). Nevertheless, a nonnegligible proportion of KTRs remains with no humoral response even after 3 doses.

Risk factors affecting the humoral response rates after 2 and 3 doses of mRNA vaccine have been suggested from cohort studies ( Table 4 ). The use of MPA seems to be associated with poor response rates. Although not very surprising, as it has already been reported for other vaccines such as influenza, 98 it is a challenging problem because MPA is widely used in KTRs.

Scarce data exist on the impact of other immunosuppressive drugs on the response rate after vaccination. A French group recently reported a low rate of humoral response rates at 6.4% after 3 doses of mRNA vaccine in KTRs treated with belatacept. 99 Also, patients treated with rituximab for rheumatic disease show very low humoral response rate after vaccination. 100 A group of experts of antineutrophil cytoplasmic antibodies vasculitis recently suggested a time window of at least 6 mo between rituximab administration and anti-SARS-CoV-2 vaccination. 101 To the best of our knowledge, there is no formal recommendation in the KT field. Mechanistic targets of rapamycin were reported to increase the humoral response after pneumococcal, tetanus, and influenza vaccines, as they increase CD8 + effector memory T cells 102, 103 ; however, the potential positive impact of mTORi on the COVID-19 vaccine-induced humoral response rate has yet to be translated into clinical data.

Less is known regarding the clinical effectiveness of vaccine in SOT recipients; however, 2 recently published studies from the United States 104 and United Kingdom 105 suggested that vaccinated SOT recipients have a reduced risk of developing symptomatic 104 and lethal forms 105 of SARS-CoV-2 infection compared with nonvaccinated SOT recipients. These preliminary results are encouraging but need validation. Moreover, correlation between vaccine-induced immune response and subsequent clinical protection is not well described yet and deserves further investigation.

KTRs infected with COVID-19 may have an increased risk of mortality compared with the general population and hemodialysis patients. Attributing this increased mortality to immunosuppression alone is imprudent, as a direct relationship has not been demonstrated so far. What is, however, clearly reported is that immunosuppression can reduce the humoral and cellular responses to vaccination; however, the interpretation of the data derived from the rapidly growing number of studies is complex because of the high heterogeneity in the use of antibody assays and neutralization platforms. Thus, until proven otherwise, immunosuppression reduction is a consideration in the early stages of infection. Handling immunosuppression in case of COVID-19 infection in KTRs should integrate the stage of infection, strength of immunosuppression, and comorbidities. Further studies will help clarify the implication of immunosuppressive drugs on KTRs' outcomes. The relationship between immunogenicity of vaccines and subsequent clinical protection needs further clarification to adapt our vaccine strategy in SOT recipients. Finally, the combination of different preventive strategies (eg, vaccination and preventive monoclonal antibody infusion) should be tested in future clinical trials. One month after the second dose.

c Placebo-controlled randomized trial including 120 KTRs demonstrated that a booster third dose (n = 60) of the mRNA-1273 vaccine given 2 mo after the second dose was associated with higher rates of seroconversion, anti-RBD Ab titers, and virus neutralization 1 mo after injection compared with placebo (n = 60). 

COVID-19) dashboard. Retrieved

Mortality analyses. Retrieved

COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature

A systematic review of COVID-19 infection in kidney transplant recipients: a universal effort to preserve patients' lives and allografts

A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned

Factors associated with COVID-19-related death using OpenSAFELY

Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort

Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

T-cell and antibody response after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Covid-19 and kidney transplantation

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium

ERACODA Collaborators. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study

Critical COVID-19 France Investigators. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities

Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a large research network

Mortality rates in transplant recipients and transplantation candidates in a high-prevalence COVID-19 environment

Outcomes of COVID-19 in solid organ transplant recipients: a matched cohort study

Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States

Is COVID-19 infection more severe in kidney transplant recipients?

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

COVID-19 infection: the perspectives on immune responses

Immunosuppressive agents and infectious risk in transplantation: managing the "net state of immunosuppression

Spanish Society of Nephrology COVID-19 Group. COVID-19-related mortality during the first 60 days after kidney transplantation

High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: results from the Brazilian multicenter cohort study

ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation

COVID-19 in solid organ transplant: a multi-center cohort study

Immunosuppressive drugs and COVID-19: a review

Dexamethasone in hospitalized patients with Covid-19

Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: a cohort study

Hospital Clínic COVID-19 research group. A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients

The management of immunosuppression in kidney transplant recipients with COVID-19 disease: an update and systematic review of the literature

Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a By-proxy Society Recommendation Consensus approach

Management of kidney transplant immunosuppression in positive coronavirus infection requiring hospital admission

Guidance on the management of transplant recipients diagnosed with or suspected of having COVID-19 2020

Consensus guidance for organ donation and transplantation

COVID-19) for transplant clinicians

Prise en charge de l'infection due au SARS-CoV-2 chez les patients adultes transplantés d'organe solide

No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single-center experience

Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19

Corticosteroids as adjunctive therapy in the treatment of influenza

Early short-course corticosteroids in hospitalized patients with COVID-19

A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: an observational study

A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia

Bloodstream infections in critically ill patients with COVID-19

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Suppression of coronavirus replication by cyclophilin inhibitors

Cyclosporin A inhibits the replication of diverse coronaviruses

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication

High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses

Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2

Identification of candidate COVID-19 therapeutics using hPSC-derived lung organoids

TOR signaling in growth and metabolism

Everolimus with reduced calcineurin inhibitor exposure in renal transplantation

An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients

Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection

Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients

Tocilizumab in transplantation

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

HNF Hospital Tocilizumab multidisciplinary team. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

TOCI-RAF Study Group. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms

Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'more evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian centre study on tocilizumab versus standard of care

Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study

Tocilizumab in patients hospitalized with Covid-19 pneumonia

Tocilizumab in hospitalized patients with severe Covid-19 pneumonia

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study

Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary

Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation

IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/ SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

First case of COVID-19 in a kidney transplant recipient treated with belatacept

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response

Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Disappointing immunization rate after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients

Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273

Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis

Immunogenicity of BNT162b2 SARS-CoV-2 vaccine in a multicenter cohort of nursing home residents receiving maintenance hemodialysis

High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients

French Society of Transplantation. Occurrence of severe COVID-19 in vaccinated transplant patients

Severe COVID-19 by SARS-CoV-2 lineage B.1.1.7 in vaccinated solid-organ transplant recipients: new preventive strategies needed to protect immunocompromised patients. Vaccines (Basel)

Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients

Suppression of the humoral immune response by mycophenolate mofetil

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab

The effect of sirolimus therapy on vaccine responses in transplant recipients

Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses

Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients

OTDT Clinical Team. Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis